Skin Conditions & Dermatology Clinical Trials Update: Week 13, 2026

Published March 29, 2026 — 5 trials covered

By Victor Lafforgue, Founder of TrialsAlert. Blog posts are AI-drafted from ClinicalTrials.gov source data and reviewed by the editorial team. See our editorial policy for details.

A 104-Week Study of Ritlecitinib Oral Capsules in Adults With Nonsegmental Vitiligo (Active and Stable) Tranquillo 2

This Phase 3 study by Pfizer is evaluating the safety and effectiveness of ritlecitinib oral capsules for adults with nonsegmental vitiligo, a condition that causes white patches on the skin. If this treatment proves successful, it may offer a new oral medication option that could improve skin appearance and quality of life for people living with vitiligo. The study is currently recruiting adults worldwide who have had vitiligo for at least three months.

A Study to Evaluate the Efficacy, Safety, and Drug Levels of Deucravacitinib (BMS-986165) in Adolescent Participants With Moderate to Severe Plaque Psoriasis

This Phase 3 trial sponsored by Bristol-Myers Squibb is testing deucravacitinib in adolescents aged 12 to under 18 who have moderate to severe plaque psoriasis. The goal is to find a treatment that is effective and safe for younger patients, potentially providing a new option to manage this often challenging skin condition. This study is active in several countries and could lead to improved symptom control for adolescents with psoriasis.

The Impact of Salt Intake on Sodium in the Skin and Inflammatory Skin Disease

Researchers at the University of California, San Francisco are investigating whether changing salt intake affects sodium levels in the skin and the severity of inflammatory skin diseases such as atopic dermatitis and psoriasis. This Phase 4 trial could offer a simple dietary approach to help manage these common conditions if a connection is found. The study is recruiting adults in the United States and lasts for 13 weeks.

A Study With Self-administered Rocatinlimab in Adolescent and Adult Participants With Moderate-to-severe Atopic Dermatitis

In this Phase 3 study conducted by Amgen, participants with moderate-to-severe atopic dermatitis are testing rocatinlimab, a self-injectable medication. The ability to administer treatment at home could make managing this chronic skin condition more convenient and improve adherence to therapy. The trial included 151 adolescents and adults across multiple countries.

Early Detection of Skin Tumors Using a Telemedicine Tool in Primary Care

This study from the Institute of Health Information and Statistics of the Czech Republic is exploring a telemedicine tool designed to help primary care providers detect skin tumors early. By improving access to screening, this approach could lead to earlier diagnosis and better treatment outcomes for people at risk of skin cancer. The trial is recruiting in the Czech Republic and aims to enroll 1440 participants.

TrialsAlert subscribers received the full impact-classified briefing and doctor-ready report this week. Get weekly briefings at trialsalert.com.